LEHI,
Utah, July 31, 2024 /PRNewswire/ -- Halia
Therapeutics, a clinical-stage biopharmaceutical company pioneering
a novel class of small molecule medications designed to combat
inflammation, and Biolexis Therapeutics, a biotechnology company
specializing in AI-enabled drug discovery, today announced an
ongoing collaboration that successfully identified a novel
brain-penetrant small molecule candidate targeting NLRP3-driven
neuroinflammation by leveraging Biolexis'
MolecuLern™ AI-enabled approach. This milestone
represents a significant advancement in developing treatments for
neuroinflammatory disorders, including Parkinson's disease and
other neurodegenerative conditions.
"We are elated with the results of our partnership with Biolexis
Therapeutics," said David Bearss,
Ph.D., President and CEO of Halia Therapeutics and Co-Founder and
Chairman of the Board at Biolexis Therapeutics. "Biolexis'
innovative AI technology has enabled us to identify a highly
promising and novel clinical candidate that has the potential to
transform the treatment landscape for neuroinflammatory diseases.
This collaboration highlights the promising power of integrating
advanced AI tools with our expertise in neuroinflammation."
Hariprasad Vankayalapati, Ph.D.,
CSO of Biolexis Therapeutics, added, "Collaborating with Halia
Therapeutics has been a remarkable opportunity to showcase the
capabilities of our MolecuLern process. We are excited about the
potential of this new clinical candidate and eager to see it
advance through the development pipeline to ultimately offer hope
to patients with debilitating neurodegenerative diseases. This
project also underscores the strength of our AI-enabled approach in
accelerating the discovery of novel therapeutics."
Biolexis Therapeutics' MolecuLern AI-enabled approach has proven
instrumental in discovering a number of potential and innovative
therapeutic candidates with the desired efficacy and safety
profiles for protein targets associated with various diseases with
high unmet medical needs. The successful identification of a new
clinical candidate is set to advance into further preclinical
studies, aiming to offer a novel treatment option for
neuroinflammatory disorders such as Parkinson's disease.
Neuroinflammatory disorders, characterized by chronic brain
inflammation leading to progressive neuronal damage, pose
significant clinical challenges. This new therapeutic approach
seeks to overcome these challenges by addressing the root causes of
these debilitating conditions specifically targeting NLRP3-driven
neuroinflammation.
About Halia Therapeutics
Halia Therapeutics is discovering and developing a pipeline of
novel therapeutics to improve patients' lives with chronic
inflammatory disorders and neurodegenerative diseases, with its
initial programs targeting NEK7 and LRRK2. Halia's lead candidate,
HT-6184, a novel NEK7/NLRP3 inhibitor, has completed a Phase I
study (NCT05447546) evaluating the safety and tolerability
of HT-6184 when administered as single or multiple oral doses at
escalating dose levels in healthy volunteer subjects. Halia also
has 2 ongoing Phase II trials evaluating the efficacy of HT-6184
for the treatment of lower-risk myelodysplastic syndromes (LR-MDS)
and on post-procedure diagnostic biomarkers of inflammation and
pain (NCT06241742).
The company's headquarters are in Lehi, Utah. For more information, visit
www.haliatx.com or follow us on LinkedIn and X.
About Biolexis Therapeutics
Biolexis Therapeutics is a biotechnology company specializing in
AI-enabled drug discovery. Utilizing its proprietary
MolecuLern™ process, Biolexis accelerates the
identification and development of novel therapeutic candidates,
addressing various medical challenges through leading-edge
technology.
The company's headquarters are in American Fork, Utah. For more information,
visit www.biolexistx.com or follow us on LinkedIn.
Company Contacts:
James Dye
Director of Communications
Halia Therapeutics
Email: info@haliatx.com
Phone: +1.385.355.4315
Kyle Medley
Director Business Development
Biolexis Therapeutics
Email: kmedley@biolexistx.com
Phone: 435-893-5473
Media Contact:
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
+1 (646) 942-5604
Ignacio.Guerrero-Ros@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halia-therapeutics-and-biolexis-therapeutics-partnership-successfully-identifies-novel-clinical-candidate-targeting-nlrp3-driven-neuroinflammation-302210473.html
SOURCE Halia Therapeutics